Geron Financials

GERN Stock  USD 1.64  0.03  1.80%   
Based on the analysis of Geron's profitability, liquidity, and operating efficiency, Geron may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Geron's Non Currrent Assets Other are very stable compared to the past year. As of the 17th of March 2025, Cash And Short Term Investments is likely to grow to about 426.9 M, while Short and Long Term Debt Total is likely to drop about 3.1 M. Key indicators impacting Geron's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.0110.0116
Notably Down
Slightly volatile
Current Ratio10.535.5606
Way Up
Pretty Stable
The financial analysis of Geron is a critical element in measuring its lifeblood. Investors should not minimize Geron's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(165.84 Million)

  
Understanding current and past Geron Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Geron's financial statements are interrelated, with each one affecting the others. For example, an increase in Geron's assets may result in an increase in income on the income statement.

Geron Stock Summary

Geron competes with Viking Therapeutics, TG Therapeutics, X4 Pharmaceuticals, PDS Biotechnology, and Madrigal Pharmaceuticals. Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. The company was incorporated in 1990 and is headquartered in Foster City, California. Geron Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS3741631036
CUSIP374163103
LocationCalifornia; U.S.A
Business Address919 East Hillsdale
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.geron.com
Phone650 473 7700
CurrencyUSD - US Dollar

Geron Key Financial Ratios

Geron Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets270.7M226.0M190.6M394.1M593.8M623.5M
Other Current Liab22.3M37.0M44.6M54.1M77.8M81.6M
Net Debt19.4M20.1M(1.5M)15.9M(75.8M)(72.0M)
Retained Earnings(1.2B)(1.3B)(1.4B)(1.6B)(1.8B)(1.7B)
Accounts Payable6.9M6.7M10.2M6.2M8.6M9.0M
Cash10.3M34.9M57.2M70.0M79.0M42.1M
Other Current Assets2.9M1.7M4.4M6.0M9.8M10.3M
Total Liab59.8M99.6M110.6M146.1M313.5M329.1M
Total Current Assets199.9M187.2M180.2M341.3M491.0M515.5M
Short Term Debt1.8M1.8M21.9M47.8M1.9M1.9M
Net Receivables722K1.8M3.1M1.7M35.9M37.7M
Common Stock310K324K390K545K606K636.3K
Other Assets1.5M4.8M5.4M98.6M113.4M119.1M
Inventory(802K)(722K)(1.4M)(3.1M)38.7M40.6M
Net Tangible Assets137.4M210.9M126.4M80.0M92.0M139.7M
Capital Surpluse1.2B1.4B1.4B1.5B1.7B1.3B
Net Invested Capital235.0M176.2M131.2M329.9M398.8M232.1M
Net Working Capital168.9M141.7M103.6M233.3M402.7M422.8M

Geron Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense760K3.7M6.9M8.3M18.5M19.4M
Total Revenue253K1.4M596K237K77.0M80.8M
Gross Profit(49.8M)610K(272K)(123.5M)75.7M79.5M
Operating Income(76.9M)(114.0M)(138.6M)(193.9M)(173.7M)(165.0M)
Ebit(74.9M)(112.4M)(135.0M)(175.8M)(156.1M)(148.3M)
Research Development51.5M85.7M95.5M125.0M103.7M108.9M
Ebitda(73.9M)(111.6M)(134.2M)(174.8M)(154.8M)(147.1M)
Cost Of Revenue50.1M783K868K123.7M1.3M1.2M
Income Before Tax(75.6M)(116.1M)(141.9M)(184.1M)(174.6M)(165.8M)
Net Income(75.6M)(121.0M)(141.0M)(184.1M)(174.6M)(165.8M)
Income Tax Expense(7K)4.8M(868K)1.00.90.86
Interest Income1.8M527K2.5M18.2M19.6M20.6M
Net Interest Income1.1M(3.2M)(4.4M)9.8M1.1M1.8M

Geron Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash(3.6M)24.9M22.0M13.9M9.7M10.2M
Free Cash Flow(67.1M)(95.8M)(127.8M)(168.6M)(219.3M)(208.3M)
Depreciation935K783K868K1.0M1.2M1.4M
Other Non Cash Items264K984K626K(10.1M)(45.4M)(43.1M)
Capital Expenditures401K207K431K830K680K684.7K
Net Income(75.6M)(116.1M)(141.9M)(184.1M)(174.6M)(165.8M)
End Period Cash Flow10.3M35.2M57.2M71.1M80.9M42.1M
Investments(105.3M)70.6M62.5M(180.3M)(106.0M)(100.7M)
Change To Netincome6.4M6.7M6.9M8.3M9.5M7.1M

Geron Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Geron's current stock value. Our valuation model uses many indicators to compare Geron value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Geron competition to find correlations between indicators driving Geron's intrinsic value. More Info.
Geron is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Geron's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Geron's earnings, one of the primary drivers of an investment's value.

Geron Systematic Risk

Geron's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Geron volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Geron correlated with the market. If Beta is less than 0 Geron generally moves in the opposite direction as compared to the market. If Geron Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Geron is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Geron is generally in the same direction as the market. If Beta > 1 Geron moves generally in the same direction as, but more than the movement of the benchmark.

Geron Thematic Clasifications

Geron is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
Cancer FightersView
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
Today, most investors in Geron Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Geron's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Geron growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.88

At this time, Geron's Price Earnings To Growth Ratio is very stable compared to the past year.

Geron March 17, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Geron help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Geron. We use our internally-developed statistical techniques to arrive at the intrinsic value of Geron based on widely used predictive technical indicators. In general, we focus on analyzing Geron Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Geron's daily price indicators and compare them against related drivers.
When determining whether Geron offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Geron's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Geron Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Geron Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.27)
Revenue Per Share
0.119
Quarterly Revenue Growth
2.1 K
Return On Assets
(0.22)
Return On Equity
(0.66)
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.